文献速递心外重症与机械循环支持

机械辅助循环支持机构注册报告:全人工心脏

Interagency registry for mechanically assisted circulatory support report on the total artificial heart.
PubMed 文献 · J Heart Lung Transplant · 2018-04-26

基于INTERMACS数据库2006年6月至2017年4月450例临时全人工心脏(TAH)患者数据,评估生存、不良事件与竞争结局。总体3、6、12个月生存率分别为73%、62%、53%;高龄、植入前透析、较高肌酐、较低白蛋白及低容量中心植入与死亡风险相关。高容量中心12个月存活或移植比例为71%,低容量中心为57%(p=0.003)。

要点

  • 450例TAH患者中87%为男性,平均年龄50岁,扩张型心肌病占50%、缺血性心肌病占20%。
  • 82%患者存在右心衰竭危险因素,植入时INTERMACS Profile 1占43%、2占37%。
  • 高容量中心12个月存活或移植71% vs 低容量中心57%(p=0.003)。

核心结论

  • 接受TAH的患者心脏功能快速下降,需要及时干预。
  • 有经验的中心结局更好,可能与患者选择、植入时机、患者护理和设备管理有关。
  • 有组织地向低容量中心转移知识可能改善结局。

研究设计与样本

  • 基于INTERMACS数据库的注册报告,纳入2006年6月至2017年4月接受TAH的患者450例,使用风险函数分析探索死亡危险因素。

主要发现

  • 450例患者中87%为男性,平均年龄50岁;扩张型心肌病占50%,缺血性心肌病占20%。
  • 82%患者存在右心衰竭危险因素;INTERMACS Profile 1占43%,Profile 2占37%。
  • 266例最终接受移植,162例死亡;总体3、6、12个月 actuarial 生存率分别为73%、62%、53%。
  • 死亡危险因素包括年龄较大(p=0.001)、植入前需要透析(p=0.006)、较高肌酐(p=0.008)、较低白蛋白(p<0.001)及在低容量中心(≤10例TAH;p<0.001)植入。
  • 竞争结局分析显示,高容量中心12个月时存活于装置上或已接受移植的患者比例为71%,低容量中心为57%(p=0.003)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We sought to better understand the patient population who receive a temporary total artificial heart (TAH) as bridge to transplant or as bridge to decision by evaluating data from the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) database. METHODS: We examined data related to survival, adverse events, and competing outcomes from patients who received TAHs between June 2006 and April 2017 and used hazard function analysis to explore risk factors for mortality. RESULTS: Data from 450 patients (87% men; mean age, 50 years) were available in the INTERMACS database. The 2 most common diagnoses were dilated cardiomyopathy (50%) and ischemic cardiomyopathy (20%). Risk factors for right heart failure were present in 82% of patients. Most patients were INTERMACS Profile 1 (43%) or 2 (37%) at implantation. There were 266 patients who eventually underwent transplantation, and 162 died. Overall 3-, 6-, and 12-month actuarial survival rates were 73%, 62%, and 53%, respectively. Risk factors for death included older age (p = 0.001), need for pre-implantation dialysis (p = 0.006), higher creatinine (p = 0.008) and lower albumin (p < 0.001) levels, and implantation at a low-volume center (≤10 TAHs; p < 0.001). Competing-outcomes analysis showed 71% of patients in high-volume centers were alive on the device or had undergone transplantation at 12 months after TAH implantation vs 57% in low-volume centers (p = 0.003). CONCLUSIONS: Patients receiving TAHs have rapidly declining cardiac function and require prompt intervention. Experienced centers have better outcomes, likely related to patient selection, timing of implantation, patient care, and device management. Organized transfer of knowledge to low-volume centers could improve outcomes.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Arabía FA, Cantor RS, Koehl DA, et al. Interagency registry for mechanically assisted circulatory support report on the total artificial heart. J Heart Lung Transplant. 2018. PMID: 29802083. doi:10.1016/j.healun.2018.04.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。